Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 802-808

  Kortenhorst, Madeleine S Q ^a,c   Isharwal, Sumit ^b   Van Diest, Paul J ^c   Chowdhury, Wasim H ^b   Marlow, Cameron ^b   Carducci, Michael A ^a   Rodriguez, Ronald ^b   Veltri, Robert W ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; VALPROIC ACID; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER MODEL; CELL LINE; CELL NUCLEUS; CELL STRAIN LNCAP; CONTROLLED STUDY; DIGITAL IMAGING; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STAINING; TISSUE MICROARRAY; TUMOR XENOGRAFT; ANIMAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENETICS; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TIME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; KIDNEY; LIVER; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; TIME FACTORS; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66449127641     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1076     Document Type: Article

References (64)

1. Kortenhorst MS, Carducci MA, Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer. Cell Oncol 2006;28:191-222. (Pubitemid 44950093)
2. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-299 (Pubitemid 37361445)
3. Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008;9:139-148
4. Reid T, Valone F, Lipera W, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004;45:381-386 (Pubitemid 39037720)
5. Kelly WK, O'Connor OA, Krug LM, et al. Phase I studyof an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931 (Pubitemid 46218695)
6. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97:177-182 (Pubitemid 47057472)
7. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-2308 (Pubitemid 47523148)
8. Kim B, Ahn K, Kim I, Park I, Kim B, Yoon S. Effect of combined treatment of bortezomib and valproic acid on multiple myeloma cells. ASCO Annu Meet Proc Part I 2007;18539.
9. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008;14:6296-6301
10. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-1985 (Pubitemid 46972780)
11. Waterborg JH. Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem Cell Biol 2002;80:363-378
12. Escargueil AE, Soares DG, Salvador M, Larsen AK, Henriques JA. What histone code for DNA repair? Mutat Res 2008;658:259-270
13. Polevoda B, Sherman F. The diversity of acetylated proteins. Genome Biol 2002;3:reviews0006. (Pubitemid 34578281)
14. Ferguson M, Henry PA, Currie RA. Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. Nucleic Acids Res 2003;31:3123-3133 (Pubitemid 37441772)
15. Zhang Q, Wang Y. High mobility group proteins and their post-translational modifications. Biochim Biophys Acta 2008;1784:1159-1166
16. Lim JH, West KL, Rubinstein Y, Bergel M, Postnikov YV, Bustin M. Chromosomal protein HMGN1 enhances the acetylation of lysine 14 in histone H3. EMBO J 2005;24:3038-3048 (Pubitemid 41486340)
17. Belova GI, Postnikov YV, Furusawa T, Birger Y, Bustin M. Chromosomal protein HMGN1 enhances the heat shock-induced remodeling of Hsp70 chromatin. J Biol Chem 2008;283:8080-8088
18. Townson SM, Kang K, Lee AV, Oesterreich S. Structure-function analysis of the estrogen receptor α corepressor scaffold attachment factor-B1: identification of a potent transcriptional repression domain. J Biol Chem 2004;279:26074-26081 (Pubitemid 38798751)
19. MacRae TH. Tubulin post-translational modifications - enzymes and their mechanisms of action. Eur J Biochem 1997;244:265-278 (Pubitemid 27110726)
20. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-4394 (Pubitemid 36457739)
21. Yamamichi N, Yamamichi-Nishina M, Mizutani T, et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 2005;24:5471-5481 (Pubitemid 43080090)
22. Diamond DA, Berry SJ, Jewett HJ, Eggleston JC, Coffey DS. A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J Urol 1982;128:729-734 (Pubitemid 13236343)
23. Veltri RW, Miller MC, Isharwal S, Marlow C, Makarov DV, Partin AW. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Cancer Epidemiol Biomarkers Prev 2008;17:102-110
24. Veltri RW, Khan MA, Miller MC, et al. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004;10:3465-3473 (Pubitemid 38685454)
25. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 1989;142:1254-1258 (Pubitemid 19277958)
26. Epstein JI, Berry SJ, Eggleston JC. Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer. Cancer 1984;54:1666-1671
27. Huisman A, Ploeger LS, Dullens HF, et al. Discrimination between benign and malignant prostate tissue using chromatin texture analysis in 3-D by confocal laser scanning microscopy. Prostate 2007;67:248-254 (Pubitemid 46255783)
28. Jorgensen T, Yogesan K, Tveter KJ, Skjorten F, Danielsen HE. Nuclear texture analysis: a new prognostic tool in metastatic prostate cancer. Cytometry 1996;24:277-283 (Pubitemid 26233290)
29. Stein GS, Lian JB, Stein JL, et al. Combinatorial organization of the transcriptional regulatory machinery in biological control and cancer. Adv Enzyme Regul 2005;45:136-154 (Pubitemid 41739480)
30. 2 disease. J Urol 1995;153:1015-1019
31. Gill JE, Jotz MM. Further observations on the chemistry of pararosaniline-Feulgen staining. Histochemistry 1976;46:147-160
32. Schulte E, Wittekind D. Standardization of the Feulgen-Schiff technique. Staining characteristics of pure fuchsin dyes; a cytophotometric investigation. Histochemistry 1989;91:321-331
33. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998;391:815-818 (Pubitemid 28099683)
34. Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E, Castronovo V. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem 2004;48:273-290
35. Kachhap SK, Kortenhorst MSQ, Shabbeer S, Washington E, Carducci MA. Comparison of expression of class I and class II histone deacetylase in prostate cancer cell lines and normal immortalized prostate epithelial cells. Proc AACR Annu Meet 2005;46:648 (abstr 2751).
36. Kortenhorst MS, Zahurak M, Shabbeer S, et al. A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin Cancer Res 2008;14:6886-6894
37. Lanctot C, Cheutin T, Cremer M, Cavalli G, Cremer T. Dynamic genome architecture in the nuclear space: regulation of gene expression in three dimensions. Nat Rev Genet 2007;8:104-115 (Pubitemid 46122840)
38. Gasser SM. Visualizing chromatin dynamics in interphase nuclei. Science 2002;296:1412-1416
39. Cremer T, Cremer M, Dietzel S, Muller S, Solovei I, Fakan S. Chromosome territories - a functional nuclear landscape. Curr Opin Cell Biol 2006;18:307-316
40. Chubb JR, Boyle S, Perry P, Bickmore WA. Chromatin motion is constrained byasso ciation with nuclear compartments in human cells. Curr Biol 2002;12:439-445 (Pubitemid 34248889)
41. 1. Curr Biol 2004;14:166-172
42. Heun P, Laroche T, Shimada K, Furrer P, Gasser SM. Chromosome dynamics in the yeast interphase nucleus. Science 2001;294:2181-2186 (Pubitemid 33150678)
43. Levi V, Ruan Q, Plutz M, Belmont AS, Gratton E. Chromatin dynamics in interphase cells revealed by tracking in a two-photon excitation microscope. Biophys J 2005;89:4275-4285 (Pubitemid 41725646)
44. Chuang CH, Carpenter AE, Fuchsova B, Johnson T, de Lanerolle P, Belmont AS. Long-range directional movement of an interphase chromosome site. Curr Biol 2006;16:825-831
45. Kosak ST, Skok JA, Medina KL, et al. Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science 2002;296:158-162 (Pubitemid 34280078)
46. Hewitt SL, High FA, Reiner SL, Fisher AG, Merkenschlager M. Nuclear repositioning marks the selective exclusion of lineage-inappropriate transcription factor loci during T helper cell differentiation. Eur J Immunol 2004;34:3604-3613 (Pubitemid 40012178)
47. Williams RR, Azuara V, Perry P, et al. Neural induction promotes large-scale chromatin reorganisation of the Mash1 locus. J Cell Sci 2006;119:132-140 (Pubitemid 43169306)
48. Zink D, Amaral MD, Englmann A, et al. Transcription-dependent spatial arrangements of CFTR and adjacent genes in human cell nuclei. J Cell Biol 2004;166:815-825 (Pubitemid 39249833)
49. Ragoczy T, Bender MA, Telling A, Byron R, Groudine M. The locus control region is required for association of the murine β-globin locus with engaged transcription factories during erythroid maturation. Genes Dev 2006;20:1447-1457 (Pubitemid 43830652)
50. Spilianakis CG, Lalioti MD, Town T, Lee GR, Flavell RA. Interchromosomal associations between alternatively expressed loci. Nature 2005;435:637-645 (Pubitemid 40825504)
51. Simonis M, Klous P, Splinter E, et al. Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C). Nat Genet 2006;38:1348-1354 (Pubitemid 44646300)
52. Gilman AG, Rall TW, Nies AS, Taylor P. Goodman and Gilman's the pharmacological basis of therapeutics. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990 pp. 450-453
53. Altunbasak S, Yildizas D, Anarat A, Burgut HR. Renal tubular dysfunction in epileptic children on valproic acid therapy. Pediatr Nephrol 2001;16:256-259 (Pubitemid 32229848)
54. Watanabe T, Yoshikawa H, Yamazaki S, Abe Y, Abe T. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 2005;20:814-817 (Pubitemid 40663170)
55. Knorr M, Schaper J, Harjes M, Mayatepek E, Rosenbaum T. Fanconi syndrome caused by antiepileptic therapy with valproic acid. Epilepsia 2004;45:868-871 (Pubitemid 38890990)
56. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA. Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 2007;67:1099-1110 (Pubitemid 46983339)
57. Xia Q, Sung J, Chowdhury W, et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006;66:7237-7244 (Pubitemid 44197704)
58. Farrants AK. Chromatin remodelling and actin organisation. FEBS Lett 2008;582:2041-2050
59. Verstraeten VL, Lammerding J. Experimental techniques for study of chromatin mechanics in intact nuclei and living cells. Chromosome Res 2008;16:499-510.
60. Veltri RW, Marlow C, Khan MA, Miller MC, Epstein JI, Partin AW. Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate 2007;67:1202-1210
61. Makarov DV, Marlow C, Epstein JI, et al. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate 2008;68:183-189
62. Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW, Veltri RW. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 2008;68:1097-1104
63. Debes JD, Sebo TJ, Heemers HV, et al. p300 modulates nuclear morphologyin prostate cancer. Cancer Res 2005;65:708-712 (Pubitemid 40216426)
64. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638-7640 (Pubitemid 37466688)